Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC5 | O15392 | 1/20 | 0.98 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.98 |
| ▸ | SP1 | P08047 | 1/20 | 0.98 |
| ▸ | ILF3 | Q12906 | 1/20 | 0.98 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.98 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CCND1 | P24385 | 1/20 | 0.35 |
| ▸ | CCND2 | P30279 | 1/20 | 0.35 |
| ▸ | CCND3 | P30281 | 1/20 | 0.35 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sepantronium SCHEMBL2814447 | 1.00 | BIRC5 (0.98) | BIRC5RIPK2SP1ILF3PAK1 | |
| Sepantronium SCHEMBL29493286 | 0.99 | BIRC5 (1.00) | BIRC5RIPK2SP1ILF3PAK1 | |
| Sepantronium SCHEMBL727997 | 0.99 | BIRC5 (1.00) | BIRC5RIPK2SP1ILF3PAK1 | |
| Bromide SCHEMBL15062823 | 0.87 | BIRC5 (0.79) | BIRC5RIPK2SP1ILF3PAK1 | |
| SCHEMBL6190071 | 0.86 | BIRC5 (0.74) | BIRC5RIPK2SP1ILF3PAK1 | |
| SCHEMBL6190207 | 0.85 | BIRC5 (0.72) | BIRC5RIPK2SP1ILF3PAK1 | |
| Sepantronium SCHEMBL29464041 | 0.84 | BIRC5 (0.71) | BIRC5RIPK2SP1ILF3PAK1 | |
| Sepantronium SCHEMBL6188375 | 0.84 | BIRC5 (0.71) | BIRC5RIPK2SP1ILF3PAK1 | |
| Sepantronium SCHEMBL16584072 | 0.83 | BIRC5 (0.73) | BIRC5RIPK2SP1ILF3PAK1 | |
| Sepantronium SCHEMBL29379252 | 0.83 | BIRC5 (0.73) | BIRC5RIPK2SP1ILF3PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024192141-A1 | TREATMENT OF CANCERS HAVING A DRUG-RESISTANT MESENCHYMAL CELL STATE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-09-19 | — | — | WO | claimed |
| WO-2013148649-A1 | USE OF SURVIVIN ANTAGONISTS IN POLYOMAVIRUS-RELATED DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2013-10-03 | — | — | WO | claimed |
| EP-2127652-B1 | METHOD FOR TREATING CANCER USING ANTICANCER AGENT IN COMBINATION | ASTELLAS PHARMA INC (JP) | 2013-05-15 | — | — | EP | claimed |
| US-20100249413-A1 | STABILIZED PHARMACEUTICAL COMPOSITION | ASTELLAS PHARMA INC. (JP) | 2010-09-30 | — | — | US | claimed |
| EP-2055304-A1 | STABILIZED PHARMACEUTICAL COMPOSITION | Astellas Pharma Inc. (JP) | 2009-05-06 | — | — | EP | claimed |
| US-20260125683-A1 | TREATMENT OF CANCERS HAVING A DRUG-RESISTANT MESENCHYMAL CELL STATE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12268690-B2 | Treatments for mutations in acute myeloid leukemia | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240033265-A2 | TREATMENTS FOR MUTATIONS IN ACUTE MYELOID LEUKEMIA | OREGON HEALTH & SCIENCE UNIVERSITY | 2024-02-01 | — | — | US | disclosed |
| US-20230330086-A1 | ANTIPROLIFERATIVE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | SIGNAL PHARMACEUTICALS, LLC | 2023-10-19 | — | — | US | disclosed |
| US-20230255975-A1 | METHODS FOR TREATING CANCER WITH COMBINATION THERAPIES | CELGENE CORPORATION | 2023-08-17 | — | — | US | disclosed |
| US-11660297-B2 | Antiproliferative compounds and second active agents for combined use | CELGENE CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230158037-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION | 2023-05-25 | — | — | US | disclosed |
| EP-2055304-A1 | STABILIZED PHARMACEUTICAL COMPOSITION | Astellas Pharma Inc. (JP) | 2009-05-06 | — | — | EP | disclosed |
| US-20080166344-A1 | METHOD OF TREATING CANCER BY CO-ADMINISTRATION OF ANTICANCER AGENTS | ASTELLAS PHARMA INC. (JP) | 2008-07-10 | — | — | US | disclosed |
| WO-2008081927-A1 | METHOD FOR TREATING CANCER USING ANTICANCER AGENT IN COMBINATION | ASTELLAS PHARMA INC. (JP) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008023807-A1 | STABILIZED PHARMACEUTICAL COMPOSITION | ASTELLAS PHARMA INC. (JP) | 2008-02-28 | — | — | WO | disclosed |
| US-20060223831-A1 | Bromide and its crystal | ASTELLAS PHARMA INC. (JP) | 2006-10-05 | — | — | US | disclosed |
| EP-1614686-A1 | BROMIDE AND ITS CRYSTAL | Astellas Pharma Inc. (JP) | 2006-01-11 | — | — | EP | disclosed |
| JP-2004331657-A | BROMIDE AND ITS CRYSTAL | YAMANOUCHI PHARMACEUT CO LTD | 2004-11-25 | — | — | JP | disclosed |
| WO-2004092160-A1 | BROMIDE AND ITS CRYSTAL | ASTELLAS PHARMA INC. (JP) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223831-A1 | Bromide and its crystal | B2M, PBRM1, POLM | BIRC5 1109/4885RIPK2 3146/4885SP1 4106/4885 |
| US-20230158037-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | DOT1L, CARM1, EZH2 | BIRC5 235/4885RIPK2 465/4885SP1 1600/4885 |
| US-11660297-B2 | Antiproliferative compounds and second active agents for combined use | NEK4, NEK1, AURKB | BIRC5 530/4885RIPK2 253/4885SP1 1261/4885 |
| US-20080166344-A1 | METHOD OF TREATING CANCER BY CO-ADMINISTRATION OF ANTICANCER AGENTS | DCK, TOP2A, RRM1 | BIRC5 441/4885RIPK2 590/4885SP1 4137/4885 |
| US-20230255975-A1 | METHODS FOR TREATING CANCER WITH COMBINATION THERAPIES | NEK1, NEK11, CDK9 | BIRC5 655/4885RIPK2 219/4885SP1 1063/4885 |
| US-20260125683-A1 | TREATMENT OF CANCERS HAVING A DRUG-RESISTANT MESENCHYMAL CELL STATE | ACTR2, RPS6KB2, EPB41L2 | BIRC5 2130/4885RIPK2 1392/4885SP1 4064/4885 |
| US-20230330086-A1 | ANTIPROLIFERATIVE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | NEK4, AURKB, XPO1 | BIRC5 450/4885RIPK2 243/4885SP1 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.